Zhejiang Cellyan Biotechnology

Cellyan Biotechnology is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, specializing in the development of innovative cell therapies for cancer. The company focuses on chimeric antigen receptor T-cell (CAR-T) technologies, targeting both hematological malignancies and solid tumors. Their lead programs include advanced CAR-T candidates for CD19-positive leukemias and lymphomas, as well as BCMA-targeted therapies for multiple myeloma. Cellyan leverages a proprietary manufacturing platform designed to improve the efficacy and safety profile of cell-based medicines while reducing production costs. The company aims to provide accessible and high-quality immunotherapy solutions to patients globally.